4 responses to “Age-Related Macular Degeneration: New treatments that changed my practice”

  1. I did not realize that the evidence for the use of AREDS was so strong so I will begin using them regularly.

  2. Good summary. Wondering: What are the NNT? And what are the $ costs to patients?

  3. also wondering, how long the studies went out and any other morbidity and mortality issues identified, besides the lung cancer/beta carotene link.

  4. Why are you adding Lutein and Omega-3 fatty acid to treatment in smokers and patients with tolerance problems if the study did not show any benefit.
    “The AREDS 2 study left people on the AREDS formula but added either lutein and zeaxanthin, omega-3 fatty acids or both. The study found no additive effect of these agents on the standard AREDS baseline.”

Leave a Reply